Completed Trials

AHCC 08

Hepatocellular Carcinoma Registry In Asia (NCT03233360)

Status

Completed recruitment of 2533 participants in December 2019.

Preliminary results presented at ASCO 2018, ILCA (2018) and APPLE (2019).

Pending Publication

Contributing Principal Investigators and Centres

Australia

Edmund Tse (Royal Adelaide Hospital), Prof Simone Strasser (Royal Prince Alfred Hospital)

China

Li Lequn (Guangxi Medical University Cancer Center), Jiangtao Li (Second Affiliated Hospital Zhejiang University School of Medicine), Fan Jia (Zhongshan Hospital, Fudan University), Zhu Xu (Beijing Cancer Hospital), Yuxian Bai (Harbin Medical University Cancer Hospital), Qin Shu-Kui (Nanjing Bayi Hospital)

Hong Kong

Prof Thomas Yau (Queen Mary Hospital)

Japan

Masatoshi Kudo (Kindai University Hospital), Junji Furuse (Kyorin University School of Medicine), Kazuaki Shimada (National Cancer Centre), Kiyoshi Hasegawa, (University of Tokyo), Nobuyuki Takemura (National Center of Global Health and Medicine)

New Zealand

Adam Bartlett (Auckland City Hospital)

Singapore

Pierce Chow (National Cancer Centre), Dan Yock Young (National University Hospital), Brian Goh (Singapore General Hospital)

South Korea

Hyun-Ki Yoon (Asan Medical Centre), Kim Yun-Hwan (Korea University Anam Hospital), Joon-Hyeok Lee (Samsung Medical), Ho-Seong Han (Seoul National University Hospital), Yang Jin-Mo (St Vincents Hospital), Choi Jong-Young (St. Mary’s Hospital), Hee-Jung Wang (Ajou University Hospital), Do-Young Kim (Severance Hospital, Yonsei University College of Medicine)

Taiwan

Peng-Cheng Yuan (China Medical University Hospital), Yee Chao (Taipei Veterans General Hospital), Tsung-Hui Hu (KS-Chang Gung Memorial Hospital), Pin-Nan Cheng (National Cheng Kung University Hospital), Chien-Hung Chen (National Taiwan University Hospital)

Thailand

Rawisak Chanwat (National Cancer Institute), Supot Ninanong (Siriraj Hospital, Mahidol University)

Protocol Chair Pierce Chow 
pierce.chow.k.h@singhealth.com.sg
AHCC 07

Precision Medicine in Liver Cancer across an Asia-Pacific Network (The PLANet Study) (NCT03267641)

Status

Completed recruitment of 120 patients in March 2021.

Two main publications in Cell (DOI: 10.1016/j.cell.2020.08.040) and Nature Communications (DOI: 10.1038/s41467-020-20171-7).

Contributing Principal
Investigators and Centres

Malaysia

Yoong Boon Koon (University Malaya Medical Center)

Philippines

Maria Vanessa H. de Villa (The Medical City)

Singapore

Pierce Chow (National Cancer Centre), Glenn Bonney (National University Hospital), Brian Goh (Singapore General Hospital)

Thailand

Rawisak Chanwat (National Cancer Institute)

United States of America

Sabino Zani Jr (Duke University School of Medicine)

THEME PI(S)

Theme: Genomic evolution in HCC and the discovery of novel drug targets

Name:  Zhai Weiwei

Designation:  Senior Research Scientist

Institution:  Genome Institute of Singapore

 

Theme: Translational Immunomics: Immune-phenotyping, monitoring and discovery of novel immunotherapies

Name: Salvatore Albani

Designation: Director

Institution: SingHealth Translational Immunology and Inflammation Centre

 

Theme: Clinical Trajectory and Translational Therapeutics

Name:  Pierce Chow

Designation:  Senior Consultant

Institution:  National Cancer Centre

Protocol Chair

Pierce Chow 
pierce.chow.k.h@singhealth.com.sg

AHCC 06

Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB) (NCT01135056)

Status

Complete recruitment of 360 patients in July 2018.

Results were presented at 2017 ASCO Annual Meeting on 4 June 2017.

Published in J. Clin. Oncol. (DOI: 10.1200/JCO.2017.76.0892), JMIR Res. Protoc. (DOI: 1010.2196/resprot.7016), BMC Cancer (DOI: 10.1186/s12885-016-2868-y) and Future Oncol. (DOI: 10.2217/fon-2017-0395)

Contributing Principal
Investigators and Centres

 

Brunei

Kenneth Kok (The Brunei Cancer Centre)

Indonesia

L.A Lesmana (Cipto Mangunkusumo Hospital, University of Indonesia), Tjakra Wibawa Manuaba (Sanglah General Hospital, Denpasar)

Malaysia

Aloysius Raj (Penang Adventist Hospital), Nik Azim Bin Nik Abdullah (Sarawak General Hospital), Yoong Boon Koon (University Malaya Medical Center)

Mongolia

Ariunaa Khasbazar (National Cancer Center of Mongolia)

Myanmar

Khin Maung Win (Yangon GI & Liver Centre)

New Zealand

Adam Bartlett (Auckland City Hospital)

Philippines

Rolley Lobo (Davao Doctors Hospital), Catherine Teh (Makati Medical Center), Janus Ong (The Medical City), Ian Cua (St Luke’s Medical Center)

Singapore

Kenneth Mak (Khoo Teck Puat Hospital), David Tai (National Cancer Centre), Dan Yock Young (National University Hospital), Cheow Peng Chung (Singapore General Hospital)

South Korea

Hyun-Ki Yoon (Asan Medical Center), Yun-Hwan Kim (Korea University Anam Hospital), Ho-Seong Han (Seoul National University Bundang Hospital) Si-Hyun Bae (Seoul St Mary’s Hospital), Jong Yun Won (Severance Hospital, Yonsei University), Jin-Mo Yang (St Vincent’s Hospital)

Taiwan

Chien-Fu Hung (Chang Gung Memorial Hospital), Chao-Long Chen (Chang Gung Memorial Hospital, Kaohsiung), Cheng-Yuan Peng (China Medical University Hospital), Po-Chin Liang (National Taiwan University Hospital), Rheun-Chuan Lee (Taipei Veterans General Hospital)

Thailand

Chanisa Chotipanich (Chulabhorn Hospital)

 

Protocol Chair

Pierce Chow 
pierce.chow.k.h@singhealth.com.sg

AHCC 05

Phase I/II Study of SIR-Spheres plus Sorafenib (Chemo-Radiotherapy) as First Line Treatment in Patients with Non-Resectable Primary Hepatocellular Carcinoma

Status

Completed in June 2009 with recruitment of 35 patients. Published in PLoS ONE 2014 9(3):e90909. doi: 10.1371/journal.pone.0090909.

Contributing Principal
Investigators and Centres
Pierce Chow (SGH, Singapore), Anthony Goh (SGH, Singapore), Soo Khee Chee (NCC, Singapore), Tan Say Beng (SCRI, Singapore), Alexander Chung (SGH, Singapore), Lai Hee Kit (SGH, Singapore), Tay Kiang Hiong (SGH, Singapore), Richard Lo Hoau Gong (SGH, Singapore), Donald Poon Yee Hee (NCC, Singapore), Choo Su Pin (NCC, Singapore), Han Ho Seong (Seoul, Korea), Harjit Singh (Selayang, Malaysia), Khin Maung Win (Yangon, Myanmar)
Protocol Chair

Pierce Chow 
pierce.chow.k.h@sgh.com.sg

AHCC 04 Phase II Dose Escalating Trial of Intra-Tumoral BrachySil in Unresectable Hepatocellular Carcinoma
Status

Completed. Results Published in International Journal of Radiation Oncology *Biology* Physics Vol. 67, Issue 3, 1 March 2007; 786-792.

Contributing Principal Investigators and Centres

Pierce Chow (SGH, Singapore), Anthony Goh (SGH, Singapore), Richard Guan (Mt Elizabeth Hospital, Singapore), Foo Kian Fong, Susan Loong (NCC, Singapore), Liau Kui Hin (TTSH, Singapore), Hoang Hoa Hai (Choray Hospital, Ho Chi Minh City), Harjit Singh (Selayang Hospital, Kuala Lumpur)

Protocol Chair Pierce Chow 
pierce.chow.k.h@sgh.com.sg
AHCC 03 Randomised Trial of Adjuvant Intra-Arterial Radio-Active Iodine after Curative Resection of Hepatocellular Carcinoma
Status

Completed in March 2007 with recruitment of 103 patients. Published inWorld J Surg 6 March 2013: 1-6.

Contributing Principal Investigators and Centres

Pierce Chow (SGH, Singapore), Lucien Ooi (NCC, Singapore), Tay Khoon Hean (CGH, Singapore), Chew Soo Ping (TTSH, Singapore)

Protocol Chair London Ooi
dsoopj@nccs.com.sg
AHCC 02

Randomized Double Blind Trial of Megestrol Acetate Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma

Status

Completed in 2007 with recruitment of 204 patients. Results published in Br J Cancer 2011 September 27;105(7): 945–952. 

Contributing Principal Investigators and Centres

Pierce Chow (SGH, Singapore), Khin Maung Win (Yangon, Myanmar), Soo Khee Chee (NCC, Singapore), Hoang Hoa Hai (Ho Chi Minh City, Vietnam), Nguyen Ba Duc (Hanoi, Vietnam), Jin Mo-Yang (Suwon, Korea), Rolley Lobo (Davao City, Philippines), M Findlay (Auckland, New Zealand)

Protocol Chair Pierce Chow 
pierce.chow.k.h@sgh.com.sg
AHCC 01

Randomised Trial of Tamoxifen Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma

Status

Completed in June 2000 with recruitment of 324 patients. Results published in Hepatology 2002 36:1221-1226.

Contributing Principal Investigators and Centres

Pierce Chow (SGH, Singapore), Khin Maung Win (Yangon, Myanmar), Phillip Johnson (Shatin, Hong Kong), Soo Khee Chee (NCC, Singapore), Tan Chee Kiat (Singapore), T Manuaba (Denpasar, Indonesia), Thiravud Khuhaprema (Thailand), A Haron (Bangi, Malaysia), Si-Hyun Bae (Korea), J Cebon (Australia), M Findlay (Wellington, New Zealand)

Protocol Chair Pierce Chow 
pierce.chow.k.h@sgh.com.sg